SEOUL — The aphorism that a crisis can be an opportunity has never struck home so much as it has for vaccine companies in the era of COVID-19.
Not only has the pandemic raised awareness of the role of vaccines in health care, but it also expedited crucial advances in innovative vaccine technologies such as messenger ribonucleic acid, or mRNA, vaccines. Heightened public interest in individual vaccine firms is another plus.
Speaking to the media for the first time since assuming his role on Aug. 25, vaccine maker Sanofi Pasteur’s new general manager for Korea, Pascal Robin, underlined the significance of preventive medicine in ensuring public health care, as well as how the no…
Keep on reading: What COVID-19 means for vaccine makers